密码子对去优化的呼吸道合胞病毒减毒活疫苗在非人灵长类中具有免疫原性和效力
研究在非洲绿猴中评估了经密码子对去优化设计的呼吸道合胞病毒减毒活疫苗候选株RSV-MinL4.0(在Vero细胞中按良好生产规范生产)的减毒、免疫原性和效力。接种后病毒排出极少,诱导了与野生型感染相当的强效体液和细胞免疫应答(尽管一只动物存在基线RSV中和抗体),并在野生型RSV攻击后防止了病毒排出。结果表明RSV-MinL4.0作为减毒活疫苗具有前景,将进入临床试验以测试其安全有效保护儿童和老年人群免受RSV感染的能力。
要点
- RSV-MinL4.0接种后病毒排出极少,诱导的体液和细胞免疫应答与野生型感染相当。
- 在野生型RSV攻击后,RSV-MinL4.0能防止病毒排出。
- RSV-MinL4.0将进入临床试验,测试其保护儿童和老年人群的能力。
核心结论
- RSV-MinL4.0作为减毒活疫苗具有前景,将进入临床试验以测试其安全有效保护儿童和老年人群免受RSV感染的能力。
研究设计与样本
- 在非洲绿猴中评估RSV-MinL4.0的减毒、免疫原性和效力;RSV-MinL4.0在Vero细胞中按良好生产规范生产。
主要发现
- 接种RSV-MinL4.0后病毒排出极少。
- 接种RSV-MinL4.0诱导了强效体液和细胞免疫应答,与野生型感染相当,尽管一只动物存在基线RSV中和抗体。
- 野生型RSV攻击后,接种RSV-MinL4.0防止了病毒排出。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite a critical need for a respiratory syncytial virus (RSV) vaccine and decades of development efforts, a vaccine to protect infants, elderly, and other at-risk populations from RSV infection remains elusive. We have previously generated a new, live-attenuated vaccine candidate against RSV using rational, computer-aided gene design and chemical synthesis through a process termed viral gene "deoptimization." In this study, we assessed the attenuation, immunogenicity, and efficacy of this synthetic, live-attenuated RSV vaccine candidate, RSV-MinL4.0, in African Green Monkeys. RSV-MinL4.0 was produced under good-manufacturing-practice (GMP) in Vero cells. Vaccination with RSV-MinL4.0 resulted in minimal virus shedding after vaccination, generation of robust humoral and cellular immune responses (despite the presence of baseline RSV neutralizing antibodies in one animal) that were comparable to a wildtype infection, and protection from virus shedding post-challenge with wildtype RSV. These findings demonstrate the promise of RSV-MinL4.0 as a live-attenuated vaccine which will undergo clinical trials to test its ability to safely and effectively protect pediatric and elderly populations from infection with RSV.
引用
- Mueller S, Stauft CB, Kalkeri R, et al. A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates. Vaccine. 2020. PMID: 32107060. doi:10.1016/j.vaccine.2020.02.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。